AC
MRVI icon

Aristides Capital’s Maravai LifeSciences MRVI Stock Holding History

Aristides Capital’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-48,699
Closed -$319K – 322
2023
Q4 		$319K Buy
+48,699
New +$315K 0.12% 116
2023
Q1 		– Sell
-16,468
Closed -$236K – 219
2022
Q4 		$236K Buy
+16,468
New +$259K 0.12% 136

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Aristides Capital's MRVI Position: Q1 2024 in Review

Aristides Capital sold out of Maravai LifeSciences (MRVI) in Q1 2024, closing a stake of 48,699 shares — an estimated $319K sold.

Aristides Capital first reported a position in MRVI in Q4 2022 and held it in 2 quarters. The position peaked at $319K in Q4 2023. 210 funds tracked by Wall St. Rank hold MRVI as of Q1 2024.

  • Aristides Capital reported no remaining Maravai LifeSciences position as of Q1 2024 after selling out during the quarter.
  • Aristides Capital sold 48,699 Maravai LifeSciences shares in Q1 2024, an estimated $319K.
  • Aristides Capital first reported a position in Maravai LifeSciences in Q4 2022 and held it in 2 quarters.
  • Aristides Capital's Maravai LifeSciences position peaked at $319K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2024.

Based on Aristides Capital's 13F filing for Q1 2024, filed 15 May 2024.